Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by a mutation in the FBN1 gene, which encodes for the extracellular matrix protein fibrillin-1. The MFS clinical manifestations that lead to morbidity and mortality are primarily those involving aortic disease, such as aneurysmal dilation, aortic regurgitation, and aortic dissection. Despite the fact that 60-80% of adults with MFS have some degree of aortic disease, carotid artery aneurysms are rare and usually represent extensions of aortic dissections. 1 We report a 70-yearold female with a history of ectopia lentis and a family history of MFS who presented to the emergency department with epistaxis and anemia. An arteriogram revealed an incidental finding of bilateral carotid artery aneurysms, a rare phenomenon even in the presence of connective tissue disease. Review of the literature revealed very little data on the clinical presentation, treatment, and outcome of MFS patients with extracranial carotid artery aneurysms (ECAAs). We discuss presentation, etiology, and management options reported for these rare occurrences.
Introduction
Extracranial carotid artery aneurysms (ECAAs) are an uncommon pathology, and bilateral ECAAs represent 6-12% of carotid artery aneurysms. [2] [3] [4] [5] There can be significant diversity in the presentation of ECAAs; however, due to the frequent use of imaging in modern medicine, their discovery as an incidental finding in asymptomatic patients is increasing. The etiology of ECAAs is quite diverse and includes connective tissue diseases, such as Marfan syndrome (MFS), Ehlers-Danlos syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum. 6 MFS is caused by a mutation in the FBN1 gene that encodes for the extracellular matrix protein fibrillin-1 and has an autosomal dominant inheritance pattern. Despite the link between connective tissue disease and ECAAs, the incidence of ECAAs in MFS patients is actually quite low. 7, 8 Furthermore, there is limited research on best-practice management for these patients. We present a case of asymptomatic bilateral ECAAs in a patient who had a history suggestive of MFS and was managed with conservative therapy.
Case Report
A 70-year-old female presented to the emergency department with uncontrolled epistaxis. Her past medical history included hypertension, hyperlipidemia, hypothyroidism, type 2 diabetes mellitus, and ectopia lentis. Upon arrival, a complete blood count revealed a hemoglobin (Hgb) of 10.8 g/dL. The epistaxis initially responded to sterile tissue packing; however, she subsequently developed two recurrent episodes of epistaxis accompanied by a decrease in her Hgb to 9.2 g/dL. Cauterization of the right internal maxillary artery failed to control the bleeding; therefore, an arterial embolization was planned. Computed tomography angiography imaging was performed during arterial embolization, yielding an unexpected finding of bilateral ECAAs (Figure 1 ). The epistaxis resolved after embolization. Given the patient's history of ectopia lentis and a positive family history, MFS was most likely the underlying etiology of her vascular abnormalities. Although she had no other physical exam findings indicative of MFS, her positive family history along with her ectopia lentis qualify for a diagnosis of MFS under the Revised Ghent criterion. 9 The patient remains asymptomatic, and subsequent follow-up arteriograms at yearly intervals revealed no significant growth in the aneurysms over 2 years. There have been no additional aneurysms discovered in the patient.
Discussion
ECAAs are exceedingly rare in patients with MFS, and to the best of our knowledge, only 10 total cases have been reported in the literature. 8 In general, patients who develop ECAAs can present with a pulsatile mass, cerebral ischemic event, cranial nerve deficit, infection, dysphagia, tinnitus, bruit, hemorrhage, hoarseness, tracheal obstruction, dizziness, or without symptoms. However, in patients with MFS, the most common presentation is either asymptomatic or as a pulsatile cervical mass. 7, 10 The pathogenesis by which MFS leads to aneurysmal dilation involves the loss in functionality of the protein fibrillin-1. This extracellular matrix glycoprotein is encoded by the FBN1 gene, which undergoes mutations in patients with MFS. Malfunction of fibrillin-1 causes a loss in elasticity of a patient's arterial wall, leading to a susceptibility to aneurysms. 11 The histology of aneurysms in patients with connective tissue disease differ from those formed secondary to atherosclerotic disease, with the former consisting of cystic medial necrosis, loss of elastic fibers, and an increase in mucoid material. 1, 7 The treatment options for ECAAs include surgical or endovascular repair or conservative management, but there has yet to be a clear consensus on the best therapy. 10, 12 Surgical or endovascular interventions are typically recommended for symptomatic ECAAs, suspected infection, increasing aneurysm size, and absolute diameters greater than 2 cm. If an ECAA is to be managed surgically, options include excision with primary anastomosis, excision with interposition graft, or extracranial-intracranial bypass. 7 Historically, surgical treatment was by carotid ligation, but this is no longer common practice, as it is associated with a stroke risk of 25% and a mortality rate of 20%. 5, 12, 14 In a review by Kraemer and Zhou, complication rates from open surgery showed an early risk of mortality ranging from 0 to 7%, perioperative stroke ranging from 0.7 to 11%, and cranial nerve injury ranging from 0 to 66%. Cranial nerve injuries included injuries to facial, vagus, spinal accessory, hypoglossal, and glossopharyngeal nerves. In spite of the risks, open surgery usually resulted in technical success. 10, 15 More recently, an endovascular approach has played an increasing role in the treatment of ECAAs. This approach consists of embolization of aneurysms with detachable coils and the use of stents or graft-covered stents. 2 A systematic review on endovascular interventions found procedure success to be greater than 90% with incidences of stroke of 1.8%, cranial nerve injury of 0.5%, and overall in-hospital mortality of 4.1%. The authors concluded that the high success rate and low complication rate for this approach make it feasible for continued exploration. 16 However, patients with MFS may have anatomical differences, such as elongated internal carotid arteries, which may increase the risk for kinking or thrombosis after stent placement, and therefore, may have worse outcomes with this kind of intervention. 8 Information regarding conservative therapy for ECAAs is best described by Fankhauser et al. 6 Treatments include antiplatelet therapy, anticoagulation therapy, and serial imaging. Similar to our patient, most of the patients studied were asymptomatic but also had prior imaging that revealed the stability of the aneurysm. The authors demonstrated that treating patients medically resulted in no major morbidity or mortality related to the aneurysm.
Conclusion
ECAAs are an uncommon complication with varying presentations, etiologies, and management strategies. The recommendations in the literature for treatment of this pathology vary, and there seems to be no consensus at this time. While open surgery usually achieves clinical success, it is not without risk and may be unnecessary in asymptomatic patients. Endovascular approaches have been gaining popularity, but anatomical hurdles in MFS patients may hinder the use of this approach. Conservative follow-up of asymptomatic patients with serial imaging has the least risk; however, more research is necessary to determine the threshold for treatment as far as what constitutes dangerous growth of the aneurysm and what symptoms should prompt treatment with surgery or stents rather than antiplatelet agents. The uncommon presence of bilateral ECAAs only further complicates the choice of an aggressive management strategy, given that the risk of morbidity and mortality with procedures on two arteries would likely be increased. Based on the current available evidence, patients should be apprised of the risks and benefits of treatment options and come to a joint decision with their healthcare provider.
